In a world plagued by the convergence of flu season, COVID outbreaks, RSV infections, and strep throat, the battle against antibiotic resistance has intensified. As bacteria continue to evolve and develop resistance to drugs, the medical community finds itself facing a silent pandemic. Referred to as a 'silent pandemic,' antibiotic resistance poses a grave threat to public health, with almost 3 million drug-resistant infections recorded annually in the United States alone, resulting in a staggering 35,000 deaths. Globally, the numbers are even more alarming, with an estimated 5 million deaths each year attributed to antimicrobial resistance, a figure expected to double by 2050.
One particularly troublesome bacterium is the carbapenem-resistant Acinetobacter baumannii, affectionately known in the scientific community as CRAB. This relentless pathogen ravages hospital patients, giving rise to approximately 8,500 cases and claiming around 700 lives annually in the U.S. The World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) have identified combating CRAB as a top priority for the development of effective treatments due to its resistance to crucial antibiotics.